• Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary and rapidly evolving type of adoptive cell immunotherapy that has shown tremendous promise in leveraging the body’s own immune system to direct an antitumor response.
  
  
• CST has developed a panel of detection reagents that are designed to recognize a broad range of CARs: Anti-CAR linker antibodies.
  
  
• These first-to-market reagents can be incorporated into multiparametric flow panels for monitoring CAR expression, trafficking, and persistence in pre-clinical models.
  
  

• CST has recently launched new CAR Cell Enrichment Kits to aid researchers in isolating and enriching CAR+ cells from a mixed population.
  
  

Please complete the short form on this page to request information about anti-CAR linker antibodies and CAR Cell Enrichment Kits.